May 19, 2020 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
May 12, 2020 7:30am EDT Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
May 7, 2020 7:00am EDT Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
Apr 24, 2020 7:00am EDT Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Apr 20, 2020 7:30am EDT Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020
Mar 24, 2020 5:15pm EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Mar 23, 2020 4:30pm EDT Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
Mar 3, 2020 5:00pm EST Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
Feb 28, 2020 8:45am EST Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
Feb 26, 2020 7:00am EST Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
